Local Tech Wire

RESEARCH TRIANGLE PARK, N.C. – (NYSE: GSK) and partner Human Genome Sciences have filed for regulatory approval of a drug to treat lupus, the companies said Thurdsay.

In other news, GSK said it had acquired an Arginenia-based company for $253 million.

"We and GSK have now submitted regulatory applications for Benlysta in both the United States and Europe," said H. Thomas Watkins, HGS’ chief executive officer, in a statement from HGS’ Maryland office.

"Our companies will continue to work together to achieve licensure and bring this potentially important new therapeutic option to market. Based on the results of our pivotal Phase 3 studies, HGS believes Benlysta could become the first new approved drug for systemic lupus in more than 50 years."

The companies have been working together since 2006.

Meanwhile, GSK announced the deal for Laboratorios Phoenix, a pharmaceutical firm, as part of its growth efforts in Latin America and emerging markets.

“By acquiring Phoenix, we will rapidly expand our presence in the fast growing Argentine market,” said GSK emerging markets President Abbas Hussain. “In addition, Phoenix’s broad portfolio and rich pipeline of branded generics will enable us to bring more medicines of value to patients in Argentina.”

Phoenix has a manufacturing facility near Buenos Aires. It will retain the Laboratorios Phoenix name.

GSK maintains its U.S. headquarters in RTP.

Get the latest news alerts: Follow